TregShield Bio is a next-generation immunology biotech pioneering tissue-restricted activation of biologics for safer, more effective treatment of immune and inflammatory (I&I) diseases.
Unlike conventional biologics that start acting systemically, our platform ensures activation only in diseased organs — unlocking powerful immune modulation safely.
First priority- helping people with Type 1 Diabetes (T1D) with safer, more effective disease-modifying treatment options. TRS-001 is our first-in-class, pancreas-activable biologic for T1D, featuring a dual mechanism of action:
• Neutralizing pathogenic T cells
• Boosting regulatory T cells
Beyond T1D, our platform is designed to expand across multiple high-value I&I indications.
At TregShield Bio, we believe in delivering the right drug, to the right patient, at the right location.
An Elite Team united by Innovation, Built to Execute
We bring together a uniquely complementary team of proven drug developers & biotech innovators with deep expertise across:
• Antibody engineering & immunology
• Translational & clinical drug development
• Biologics CMC & manufacturing
• Corporate strategy, BD, & licensing
Collectively, our team delivered marketed therapeutics, clinical-stage assets, & multi-million dollar licensing deals. We’re united by innovation, patient impact, & a mission to bring safer biologics to life — organ by organ.
Meet our team:
🔹 Fabien Dépis, Ph.D. – Founder, President & CEO
🔹 Maureen Deehan, Ph.D. – Independent Board Member | Corp Dev & Licensing
🔹 Olivier Léger, Ph.D. – Sr. Advisor | Antibody Engineering & Company Creation
🔹 Changyun Hu, Ph.D. – Advisor | Antibody Engineering & Immunology
🔹 Greg Elson, Ph.D. – Sr. Advisor | Biologics CMC & Product Dev
🔹 Silvia Caluwaerts, Ph.D. – Advisor | Translational & Clinical Dev
We're actively seeking mission-aligned investors, strategic biopharma partners, and supporting foundations.
Let’s build the future of precision biologics — one organ at a time
Company Details
- Employees
- 5
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.tregshield.com/
- Keywords
- Kailera Therapeutics.
Tregshield Bio Inc. Questions
Tregshield Bio Inc.'s website is https://www.tregshield.com/
Tregshield Bio Inc.'s LinkedIn profile is https://www.linkedin.com/company/tregshield-bio-inc
Tregshield Bio Inc. has
5 employees.
View email and phone details for 5
employees at Tregshield Bio Inc..
Tregshield Bio Inc.'s industry is
Biotechnology Research
Tregshield Bio Inc.'s top competitors are
Synolo Therapeutics,
Isx Financial,
Inndura Therapeutics,
Kailera Therapeutics,
Verve Therapeutics,
Hfm,
Velos Group Of Companies,
Smartlabs,
Vivtex,
Crossbow Therapeutics, Inc.
Tregshield Bio Inc.'s categories are Biotechnology Research
Tregshield Bio Inc.'s founding year is 2024
